The Purpose of This Study is to Determine the Frequency of Colorectal Cancer in Male and Female Endurance Athletes Between the Ages of 35 and 50

December 11, 2025 updated by: Inova Health Care Services

Measuring the Incidence of Colorectal Cancer in Young Endurance Athletes

The purpose of this study is to determine the frequency of colorectal cancer in male and female endurance athletes between the ages of 35 and 50.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

94

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Virginia
      • Fairfax, Virginia, United States, 22031
        • Inova Schar Cancer Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Potential participants will be recruited through distribution of a flyer at endurance events, chat rooms, and race invitations.

Description

Inclusion Criteria:

  • Adult males and females 35-50 years of age

  • Male and female self-reported endurance athletes, defined by at least one of the following:

    • Run at least two races of 50 miles or more
    • Run 5 races of 26.2 miles or more
  • Ability to complete testing in the protocol and make study visits
  • Able and willing to consent to protocol

Exclusion Criteria:

  • Known or suspected history of inflammatory bowel disease, familial adenomatous polyposis (FAP), or Lynch Syndrome
  • Concomitant illness that would prevent adequate patient assessment or in the investigators' opinion pose an added risk for study participants.
  • Anticipated poor compliance
  • Prisoners or subjects who are involuntarily incarcerated
  • Persons with decisional incapacity/cognitive impairment
  • Any history or evidence of severe illness or any other condition that would make the patient, in the opinion of the investigator unsuitable for the study
  • Subject is involved with a worker's compensation, personal injury, or other legal matters related to their health
  • Subject is enrolled in a separate interventional clinical trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The rate of young endurance runners' that have adenomatous polyps.
Time Frame: 36 months
  1. Estimate the rate of young endurance runners that have adenomatous polyps.
  2. Estimate the rate of young endurance runners that have advanced adenoma and colorectal cancer on screening colonoscopies.
36 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of the rate of young endurance athletes that have colorectal cancer on screening colonoscopies with that of the historical controls (those in the average risk group).
Time Frame: 36 months
Fisher's Exact test will be used to compare the rates of adenomatous polyps and colorectal cancer between the young endurance athletes and that of the historical controls.
36 months
Comparison of the rate of young endurance athletes that have adenomatous polyps with that of the historical controls (those in the average risk group).
Time Frame: 36 months

Fisher's Exact test will be used to compare the rates of adenomatous polyps and colorectal cancer between the young endurance athletes and that of the historical controls.

2.3 Secondary Objectives

  1. Compare the rate of young endurance runners that have adenomatous polyps with that of the historical controls (those in the average risk group)
  2. Compare the rate of young endurance runners that have advanced adenoma and colorectal cancer on screening colonoscopies with that of the historical controls (those in the average risk group).
36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Inova Health Care Services

Investigators

  • Principal Investigator: Timothy Cannon, MD, Inova Schar Cancer Institute

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 18, 2022

Primary Completion (Actual)

October 22, 2025

Study Completion (Actual)

October 22, 2025

Study Registration Dates

First Submitted

June 10, 2022

First Submitted That Met QC Criteria

June 10, 2022

First Posted (Actual)

June 15, 2022

Study Record Updates

Last Update Posted (Actual)

December 18, 2025

Last Update Submitted That Met QC Criteria

December 11, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • U21-10-4567

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe